-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga·06/23/2026 11:29:15
Listen to the news
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.